Sort   by:  
 Page size 
TranscriptomicsEnhancer-bound LDB1 Regulates a Corticotrope Promoter Pausing Repression Program [GRO-seq]
Substantial evidence supports the hypothesis that enhancers are critical regulators of cell type determination, orchestrating both positive and negative transcriptional programs; however, the basic mechanisms by which enhancers orchestrate interactions with cognate promoters during activation and re...
ORGANISM(S): Mus musculus 
2015-02-03 | E-GEOD-64515 | biostudies-arrayexpress
GenomicsEnhancer-bound LDB1 Regulates a Corticotrope Promoter Pausing Repression Program [ChIP-seq]
Substantial evidence supports the hypothesis that enhancers are critical regulators of cell type determination, orchestrating both positive and negative transcriptional programs; however, the basic mechanisms by which enhancers orchestrate interactions with cognate promoters during activation and re...
ORGANISM(S): Mus musculus 
2015-02-03 | E-GEOD-64483 | biostudies-arrayexpress
UnknownProteomic and genomic studies of non-alcoholic fatty liver disease--clues in the pathogenesis.
Not available
S-EPMC4093687 | biostudies-literature
UnknownSustained localized delivery of immunotherapy to lymph nodes reverses immunosuppression and increases long-term survival in murine glioblastoma.
Not available
S-EPMC8274437 | biostudies-literature
GenomicsEnhancer-bound LDB1 Regulates a Corticotrope Promoter Pausing Repression Program
This SuperSeries is composed of the SubSeries listed below. Refer to individual Series
ORGANISM(S): Mus musculus 
2015-02-03 | E-GEOD-64516 | biostudies-arrayexpress
MetabolomicsSmall Polar Hits against S. aureus: Screening, Initial Hit Optimization, and Metabolomic Studies
The global prevalence of antibacterial resistance requires new antibacterial drugs with novel chemical scaffolds and modes of action. It is also vital to design compounds with optimal physicochemical properties to permeate the bacterial cell envelope. We described an approach of combining and integr...
2021-11-04 | MTBLS788 | MetaboLights
UnknownProteomics and personalized PDX models identify treatment for a progressive malignancy within an actionable timeframe.
Not available
S-EPMC11982353 | biostudies-literature
UnknownTargetable lesions and proteomes predict therapy sensitivity through disease evolution in pediatric acute lymphoblastic leukemia.
Not available
S-EPMC10663560 | biostudies-literature
UnknownEpigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group.
Not available
S-EPMC3438233 | biostudies-literature
ProteomicsUncovering biological heterogeneity in endometrial carcinoma molecular subtypes by proteomic analysis
While endometrial cancer (EC) has an overall favorable prognosis, some patients do poorly and may benefit from refinements of current classification systems. Molecular classification stratifies ECs into four prognostic groups: POLEmut, MMRd (mismatch repair deficient), p53abn, and NSMP (no specific ...
ORGANISM(S): Homo sapiens (Human) 
2025-10-06 | PXD057700 | Pride
Ffpe Endometrial carcinoma Tmt 
Sort   by:  
 Page size